Who We Are
23andMe, the leading consumer genetics and research company, has accumulated a wealth of genotypic and phenotypic information from participants committed to improving human health through advances in genomics. Our Therapeutics team in South San Francisco leverages this data to discover and develop new treatments that can offer significant benefits for patients with serious, unmet medical needs.
This dedicated research and drug development group identifies novel targets using 23andMe's genetic database and performs preclinical research to advance programs towards clinical development. We currently have programs across several therapeutic areas, including but not limited to oncology, immunology, and cardiovascular diseases. More information about our Therapeutics team is available at https://therapeutics.23andme.com/.
23andMe has committed to the initiation of a postdoctoral fellowship program that would create opportunities to utilize the 23andMe human genetics platform to conduct cutting-edge science and explore novel biology. Six inaugural fellowships are being offered within the Therapeutics division. The postdoctoral fellow will be expected to focus on innovative, genetics or biological research questions with a goal of presenting their work externally at scientific meetings and publishing in top-ranked peer-reviewed journals. This opportunity will allow postdoctoral fellows to gain exposure to the biotechnology industry to either pursue a career in industry or bring the industry perspective back to an academic career. The fellowships are for a three-year period, with an optional one-year extension.
There is growing evidence of the important roles neurons play in lung physiology. One aspect of the postdoctoral research project will be to understand the implications of the neuronal-lung axis in severe asthma pathology. The second aspect of the postdoctoral research will aim to use single cell multi-omics methods (e.g. scRNAseq/scATACseq) to profile skin and blood samples from eczema patients. The resultant database will be used to generate functional hypotheses for selected novel genetic GWAS hits and to experimentally validate the role of these genes in diseases.
What You’ll Do
- Work with the Statistical Genetics group to evaluate relevant GWAS datasets
- Explore and implement methods for gene/protein expression analysis, protein localization and knockdown within neurons innervating the lung
- Execute in vitro and in vivo assays for functional validation and mechanism of action studies
- Conduct scRNAseq/scATACseq on tissue/blood samples and work with the Computational Biology/Functional Genomics team to analyze and interpret the resultant data
- Interpret, record, and present data at group meetings and other company meetings
- Present results at external scientific conferences and publish findings in peer-reviewed journals
- Maintain compliance with all company policies and procedures
What You’ll Bring
- Recent PhD in immunology, neurobiology or other biological sciences
- Hands-on experience with a broad range of cell and biochemical assays, molecular biology and mammalian cell culture techniques
- Proactive and highly self-motivated with strong analytical and troubleshooting skills
- Excellent interpersonal communication and organization skills with the ability to work independently and in a fast-paced team environment
- Experience with single cell-omics techniques and data analysis
- Multi-channel immunofluorescent imaging of lung or other tissues
- Experience with multi-channel flow cytometry and data analysis
- Familiarity with murine models of lung function & asthma
- Knowledge in the field of immunology including experience working with human and mouse primary immune cells through isolation, manipulation and functional analysis
Lino Gonzalez’s Bio
Lino Gonzalez is a Research Fellow within the Therapeutics Immunology group and has been with 23andMe for 6 years. His work focuses on new-target discovery/validation and leads a group of scientists working to advance targets in the autoimmune space. Lino was previously at Genentech for 15-years, overseeing the Receptor Discovery Biochemistry group. This group focused on the study of therapeutically important protein-receptor interactions, including targets in the Cancer Immunotherapy landscape and helped with the initial characterizations of BTLA and TIGIT. Lino completed his Ph.D. at the University of California, Berkeley in 1996, studying the structural specificity of protein interactions with Tom Alber. He did a postdoctoral fellowship at Stanford with Richard Sheller focusing on the structures and biochemical properties of neuronal membrane proteins involved in neurotransmitter release before joining Genentech in 2001. Lino has published over 35 peer reviewed scientific and review articles. In addition to his research, Lino has been a strong proponent of DEI efforts. For his contributions, Lino was recognized with a Genentech Diversity Champion corporate award. Lino has served two 3-year terms on the board of directors for SACNAS (Society for Advancement of Hispanics/Chicanos and Native Americans in Science) and served as national president of the Society from 2017-2018.
23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com.
At 23andMe, we value a diverse, inclusive workforce and we provide equal employment opportunity for all applicants and employees. All qualified applicants for employment will be considered without regard to an individual’s race, color, sex, gender identity, gender expression, religion, age, national origin or ancestry, citizenship, physical or mental disability, medical condition, family care status, marital status, domestic partner status, sexual orientation, genetic information, military or veteran status, or any other basis protected by federal, state or local laws. If you are unable to submit your application because of incompatible assistive technology or a disability, please contact us at firstname.lastname@example.org. 23andMe will reasonably accommodate qualified individuals with disabilities to the extent required by applicable law.
Please note: 23andMe does not accept agency resumes and we are not responsible for any fees related to unsolicited resumes. Thank you.